ArticleBritish journal of cancer2001
Clinical and molecular stratification of disease risk in medulloblastoma.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 168 citations in OpenAlex.
- Insights into brain tumor diagnosis: exploringFrontiers in neurology · 2024Review
- Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?Diagnostics (Basel, Switzerland) · 2023Review
- Liquid biopsy-from bench to bedside.Neuro-oncology advances · 2022Article
- CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.Frontiers in immunology · 2022Review
- Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.Frontiers in endocrinology · 2021Review
- A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.Neoplasia (New York, N.Y.) · 2018Article
- Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.Cell reports · 2017Article
- Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma.Cancer medicine · 2014Article
- Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.Acta neuropathologica communications · 2014Article
- Cytogenetic prognostication within medulloblastoma subgroups.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells.PloS one · 2014Article
- Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2013Article
- Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis.Translational oncology · 2013Article
- Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.Neuro-oncology · 2012Article
- The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.Neuro-oncology · 2012Article
- Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.Journal of neuro-oncology · 2012Article
- Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.Neuro-oncology · 2012Article
- Appraisal of the current staging system for residual medulloblastoma by volumetric analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
- Medulloblastoma comprises four distinct molecular variants.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
- Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
The accurate assessment of disease risk among children with medulloblastoma remains a major challenge to the field of paediatric neuro-oncology. In the current study we investigated the capacity of molecular abnormalities to increase the accuracy of disease risk stratification above that afforded by clinical staging alone. 41 primary medulloblastoma tumour samples were analysed for ErbB2 receptor expression using immunohistochemistry, and for aberrations of chromosome 17 and amplification of the MYC oncogene using fluorescence in situ hybridisation. The ErbB2 receptor and deletion of 17p were detected in 80% and 49% of tumours, respectively. 17p loss occurred either in isolation (20%), or in association with gain of 17q (29%), compatible with an isochromosome of 17q. Amplification of MYC was detected in only 2 tumours. Significant prognostic factors included, 'metastatic disease' (P = 0.0006), 'sub-total tumour resection' (P = 0.007), 'high ErbB2 receptor expression' (P = 0.003) and 'isolated 17p loss' (P = 0.003). Combined analysis of clinical and molecular factors enabled greater resolution of disease risk than clinical factors alone, identifying a sub-population of patients with particularly favourable disease outcome. These data support the hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma, thereby providing a more accurate basis for targeting therapy in children with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.